Drug Profile, Screen with Reflex to Quantitation
Ordering Recommendation
Use for general testing in contexts of compliance and/or abuse, primarily in the pain management population. Alternative testing strategies include Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2007479) and Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288).
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.
New York DOH Approval Status
Specimen Required
Random Urine.
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)
Refrigerated.
Specimens exposed to multiple freeze/thaw cycles, Pharmaceutical preparation.
Ambient: 1 week; Refrigerated: 1 month; frozen: 1 month
Methodology
Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-8 days
Reference Interval
Drugs covered and range of cutoff concentrations | |
---|---|
Drugs/Drug Classes |
Screen |
Amphetamines | 300 ng/mL |
Barbiturates | 200 ng/mL |
Benzodiazepines | 200 ng/mL |
Buprenorphine | 5 ng/mL |
Carisoprodol | 100 ng/mL |
Cocaine | 150 ng/mL |
Ethyl Glucuronide | 500 ng/mL |
Fentanyl | 1 ng/mL |
MDMA (Ecstasy) | 500 ng/mL |
Meperidine | 200 ng/mL |
Methadone | 150 ng/mL |
Opiates | 300 ng/mL |
Oxycodone | 100 ng/mL |
Phencyclidine | 25 ng/mL |
Propoxyphene | 300 ng/mL |
Tapentadol | 200 ng/mL |
Tramadol | 100 ng/mL |
THC (Cannabinoids) | 50 ng/mL |
Zolpidem | 20 ng/mL |
Interpretive Data
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and or LC MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Laboratory Developed Test (LDT)
Note
If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply.
Hotline History
Hotline History
CPT Codes
80307; if reflexed, add 80321; 80325; 80345; 80346; 80348; 80349; 80353; 80354; 80358; 80359; 80361; 80362; 80365; 80367; 80368; 80369; 80372; 80373; 83992 (Reflexed Alt Code: G0480 )
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0090386 | Creatinine, Urine | 2161-8 |
0092191 | Amphetamines, Urn, Screen | 19261-7 |
0092192 | Cocaine, Urn, Screen | 19359-9 |
0092194 | Phencyclidine, Urn, Screen | 19659-2 |
0092195 | THC, Urn, Screen | 19292-2 |
0092196 | Barbiturates, Urn, Screen | 19270-8 |
0092197 | Benzodiazepines, Urn, Screen | 14316-4 |
0092198 | Propoxyphene, Urn, Screen | 19429-0 |
0092199 | Methadone, Urn, Screen | 19550-3 |
2005094 | Opiates, Urn, Screen | 19295-5 |
2005102 | Oxycodone/Oxymorphone, Urn, Screen | 58430-0 |
2007913 | Ethyl Glucuronide Screen w/Rflx, Urine | 58375-7 |
2012212 | Screen, Urine Interpretation | 54247-2 |
2012274 | Buprenorphine, Urn, Screen | 93494-3 |
2012279 | Carisoprodol, Urn, Screen | 21142-5 |
2012285 | Fentanyl, Urn, Screen | 11235-9 |
2012289 | Meperidine, Urn, Screen | 3746-5 |
2012295 | Tapentadol, Urn, Screen | 72485-6 |
2012298 | Tramadol, Urn, Screen | 19710-3 |
2012301 | Zolpidem, Urn, Screen | 94104-7 |
Aliases
- See individual components